Genetics and the impact on treatment protocols in patients with rheumatoid arthritis

Expert Review of Clinical Immunology

Volumn 8, Issue 6, 2012, Pages 509-511

  Ibrahim, Ibrahim ^a   Owen, Sally Anne ^a   Barton, Anne ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

genetics; pharmacogenetics; predictors; response; rheumatoid arthritis; treatment

Indexed keywords

HEREDITY; HUMAN; NOTE; RHEUMATOID ARTHRITIS; TREATMENT RESPONSE;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; AZATHIOPRINE; CLINICAL PROTOCOLS; HUMANS; METHYLTRANSFERASES; PHARMACOGENETICS; POLYMORPHISM, GENETIC; PREDICTIVE VALUE OF TESTS; TREATMENT OUTCOME;

EID: 84866692471     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1586/eci.12.51     Document Type: Note

References (23)

1. Hyrich KL, Deighton C, Watson KD, Symmons DP, Lunt M; BSRBR Control Centre Consortium; British Society for Rheumatology Biologics Register. Benefit of anti-TNF therapy in rheumatoid arthritis patients with moderate disease activity. Rheumatology (Oxford). 48(10), 1323-1327 (2009).
2. Taylor PC, Feldmann M. Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis. Nat. Rev. Rheumatol. 5(10), 578-582 (2009).
3. Barrera P, van der Maas A, van Ede AE et al. Drug survival, efficacy and toxicity of monotherapy with a fully human antitumour necrosis factor-alpha antibody compared with methotrexate in longstanding rheumatoid arthritis. Rheumatology (Oxford) 41(4), 430-439 (2002).
4. Hyrich KL, Watson KD, Silman AJ, Symmons DP; British Society for Rheumatology Biologics Register. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) 45(12), 1558-1565 (2006).
5. Farragher TM, Lunt M, Fu B, Bunn D, Symmons DP. Early treatment with, and time receiving, first disease-modifying antirheumatic drug predicts long-term function in patients with inflammatory polyarthritis. Ann. Rheum. Dis. 69(4), 689-695 (2010).
6. Wiles NJ, Lunt M, Barrett EM et al. Reduced disability at five years with early treatment of inflammatory polyarthritis: results from a large observational cohort, using propensity models to adjust for disease severity. Arthritis Rheum. 44(5), 1033-1042 (2001).
7. Bukhari MA, Wiles NJ, Lunt M et al. Influence of disease-modifying therapy on radiographic outcome in inflammatory polyarthritis at five years: results from a large observational inception study. Arthritis Rheum. 48(1), 46-53 (2003).
8. Potter C, Hyrich KL, Tracey A et al.; BRAGGSS. Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis. Ann. Rheum. Dis. 68(1), 69-74 (2009).
9. Prajapati R, Plant D, Barton A. Genetic and genomic predictors of anti-TNF response. Pharmacogenomics 12(11), 1571-1585 (2011).
10. Payne K, Newman W, Fargher E, Tricker K, Bruce IN, Ollier WE. TPMT testing in rheumatology: any better than routine monitoring? Rheumatology (Oxford). 46(5), 727-729 (2007).
11. Stolk JN, Boerbooms AM, de Abreu RA et al. Reduced thiopurine methyltransferase activity and development of side effects of azathioprine treatment in patients with rheumatoid arthritis. Arthritis Rheum. 41(10), 1858-1866 (1998).
12. Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am. J. Hum. Genet. 32(5), 651-662 (1980).
13. Ujiie S, Sasaki T, Mizugaki M, Ishikawa M, Hiratsuka M. Functional characterization of 23 allelic variants of thiopurine S-methyltransferase gene (TPMT*2-*24). Pharmacogenet. Genomics 18(10), 887-893 (2008).
14. Higgs JE, Payne K, Roberts C, Newman WG. Are patients with intermediate TPMT activity at increased risk of myelosuppression when taking thiopurine medications? Pharmacogenomics 11(2), 177-188 (2010).
15. Davila L, Ranganathan P. Pharmacogenetics: implications for therapy in rheumatic diseases. Nat. Rev. Rheumatol. 7(9), 537-550 (2011).
16. Black AJ, McLeod HL, Capell HA et al. Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine. Ann. Intern. Med. 129(9), 716-718 (1998).
17. Chakravarty K, McDonald H, Pullar T et al.; British Society for Rheumatology; British Health Professionals in Rheumatology Standards, Guidelines and Audit Working Group; British Association of Dermatologists (BAD). BSR/BHPR guideline for diseasemodifying anti-rheumatic drug (DMARD) therapy in consultation with the British Association of Dermatologists. Rheumatology (Oxford). 47(6), 924-925 (2008).
18. Cooper GM, Johnson JA, Langaee TY et al. A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood. 112(4), 1022-1027 (2008).
19. Takeuchi F, McGinnis R, Bourgeois S et al. A Genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet. 5(3), e1000433 (2009).
20. Wolfe F. Comparative usefulness of C-reactive protein and erythrocyte sedimentation rate in patients with rheumatoid arthritis. J. Rheumatol. 24(8), 1477-1485 (1997).
21. Hammer HB, Odegard S, Fagerhol MK et al. Calprotectin (a major leucocyte protein) is strongly and independently correlated with joint inflammation and damage in rheumatoid arthritis. Ann. Rheum. Dis. 66(8), 1093-1097 (2007).
22. Hammer HB, Fagerhol MK, Wien TN, Kvien TK. The soluble biomarker calprotectin (a S100 protein) is associated to ultrasonographic synovitis scores and is sensitive to change in patients with rheumatoid arthritis treated with adalimumab. Arthritis Res. Ther. 13(5), R178 (2011).
23. Stahl EA, Raychaudhuri S, Remmers EF et al.; BIRAC Consortium; YEAR Consortium. Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. Nat. Genet. 42(6), 508-514 (2010).